Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
P/E ratio for Merus N.V. (MRUS)
P/E ratio as of 2023: -9.16
According to Merus N.V.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -9.16. At the end of 2022 the company had a P/E ratio of -5.30.
P/E ratio history for Merus N.V. from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -9.16 |
| 2022 | -5.30 |
| 2021 | -18.39 |
| 2020 | -6.00 |
| 2019 | -6.18 |
| 2018 | -9.80 |
| 2017 | -2.99 |
| 2016 | -5.34 |
| 2015 | -5.62 |
| 2014 | -6.04 |
| 2013 | -8.22 |
| 2012 | 0.00 |